Search

everythinglearnresearchcommunity

for

Search:↓

Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.

1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.

The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The conversation discusses the potential risks and considerations of purchasing raw Clascoterone powder from Made-In-China to create a DIY topical solution for hair loss. Concerns include fake products, low purity, and contamination, with a request for experiences and advice on reliable suppliers.

A 20-year-old is experiencing hair thinning and is considering Clascoterone and Minoxidil as treatments, avoiding finasteride due to concerns about fertility and hormones. A suggestion was made to use Clascoterone for local DHT targeting and combine it with Minoxidil for maintenance and regrowth while avoiding systemic side effects.

A male in his early 40s, who experienced side effects from finasteride, used 2.5% topical spironolactone for one year with no side effects but minimal regrowth. He plans to try a 5% spironolactone solution next.

The conversation is about the effectiveness of 0.25% topical finasteride compared to other concentrations and forms. Users discuss its potential for better scalp DHT reduction and fewer side effects, with some preferring topical over oral treatments.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

A questionable paper which suggests that 5% topical spironolactone is more effective than 0.1% topical finasteride for treating hair loss. It should be taken with a grain of salt due to the journal it was published in.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user is considering minoxidil, clascoterone, and fluridil for hair loss, avoiding finasteride and RU58841. They are also contemplating a hair transplant and exploring the resilience of transplanted hair without finasteride.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user is asking if using a 10% fluridil formulation would be effective for blocking scalp androgens in addition to their current treatment of oral dutasteride.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

RU58841 is discussed as a potential treatment for acne and hair loss, with users debating its effectiveness and safety compared to other treatments like finasteride, minoxidil, and dutasteride. Concerns about RU58841's side effects and lack of clinical trials are raised, while some users share their personal experiences and routines involving RU58841 for hair loss.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.